Join the 'Mifepristone' group to help and get support from people like you.
Posted 31 Mar 2016 by Drugs.com
WEDNESDAY, March 30, 2016 – The U.S. Food and Drug Administration is making it easier for women to obtain a medication that induces abortion. Under changes announced Wednesday by the agency, women in most states who want the drug, called mifepristone (Mifeprex), will need to make just two trips to a doctor, instead of three. They'll also have 10 weeks from the start of their last period to use the medication to terminate pregnancy, up from the prior cutoff of 49 days, The New York Times reported. Additionally, the FDA is reducing the drug's dosage from 600 milligrams to 200 mg, reportedly reducing the cost of mifepristone and its potential side effects. Abortion-rights advocates welcomed the label changes. "Unlike state and federal anti-choice laws that restrict a woman's access to an abortion, the FDA decision to make mifepristone available to more women in this country is based on ... Read more
Posted 20 Feb 2012 by Drugs.com
MONDAY, Feb. 20 – Korlym (mifepristone) has been approved by the U.S. Food and Drug Administration to treat endogenous Cushing's syndrome, a disabling disorder caused by overproduction of the so-called "stress hormone," cortisol. Cortisol is produced by the adrenal glands and increases blood sugar, making it particularly dangerous for people with diabetes. Korlym does not decrease production of the hormone, but reduces the effects of overproduction, the FDA said in a news release. The approval is for people with endogenous (of internal cause) Cushing's syndrome who have type 2 diabetes and who either haven't responded to previous surgery or aren't candidates for new surgery. Only about 5,000 people in the United States are likely to be eligible for the drug, the agency said. The medication was evaluated in clinical studies involving 50 people. Participants who took Korlym had ... Read more